Guidelines Address COVID-19 Vaccine Concerns Related to Dermal FillersFebruary 17th 2021
In the Moderna coronavirus disease 2019 (COVID-19) vaccine trials, 3 participants reported facial or lip swelling after receiving the vaccine. ASDS guidelines state that patients with a history of dermal filler injections should not void vaccinations
Venetoclax monotherapy for cutaneous BPDCNNovember 11th 2020
B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.
Skin of color patients lacking in psoriasis trialsNovember 3rd 2020
A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.
Cysteamine cream, tranexamic acid mesotherapy reveal similar efficacy, different safetyOctober 14th 2020
Cysteamine cream and tranexamic acid mesotherapy demonstrated similar efficacy but yielded different safety results when being compared as a treatment for melasma, according to a recently published study.
730 nm picosecond laser safe, effective for benign pigmented lesionsOctober 13th 2020
Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.
CD123-targeted therapies promising in BPDCN and AMLOctober 6th 2020
Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.
Skin of color patients lacking in phase 3 psoriasis trialsSeptember 17th 2020
An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.
Tagraxofusp comparable to other chemo regimens as first-line therapySeptember 4th 2020
Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.